0001213900-26-036972
SEC filingNeuroSense Therapeutics reported year-end 2025 financial results with $11.1 million net loss, $0.2 million cash position, and PrimeC Phase 3 FDA clearance in ALS.
NeuroSense Therapeutics' 2025 financial results reflect accelerated investment in its lead asset PrimeC, with R&D expenses rising 8.8% to $6.2 million due to higher share-based payments and salaries, partially offset by lower subcontractor costs. G&A expenses increased 16.6% to $4.9 million, driven by elevated share-based compensation. This contributed to a net loss of $11.1 million, up from $10.2 million in 2024, and basic/diluted EPS of -$0.44 versus -$0.54 prior year on increased shares outstanding. Balance sheet shows significant cash burn, with cash dropping to $166 thousand from $3.4 million, alongside a shift to shareholders' deficit of $1.6 million from positive equity. CEO Alon Ben-Noon highlighted 2025 as transformational, advancing PrimeC to late-stage with FDA-cleared Phase 3 PARAGON trial following Phase 2b PARADIGM's 33% progression slowing, complication reductions, and recent survival data (65% risk reduction, >14-month benefit) published in JAMA Neurology. Early Alzheimer's biomarker signals and upcoming milestones—including additional PARADIGM readouts, Phase 2 Alzheimer's data, May 2026 Health Canada pre-NDS, and PARAGON initiation—underscore PrimeC's potential across neurodegenerative diseases, though low cash raises near-term financing risks.